Despite prostate cancer being the most common male cancer in the UK, there is still no national screening programme - a gap that continues to cost lives. 

The Graham Fulford Charitable Trust (GFCT) and My PSA Tests are proud to support Prostate Cancer Research (PCR) in their ongoing mission to make a targeted national prostate cancer screening programme a reality. Yesterday, Graham Fulford MBE, Founder of GFCT, attended the All Party Parliamentary Group at the House of Commons, hosted by PCR, for the launch of their landmark report, “Prostate Cancer Screening: The Impact on the NHS.” 

The report presents compelling evidence that a targeted screening programme for high-risk men - including those with a family history of prostate cancer, Black men, and those with the BRCA2 gene mutation - could significantly improve early detection and reduce deaths, all while costing just 0.01% of the NHS annual budget. 

The message from the day was clear: targeted screening saves lives. 

Graham reflected on the event, saying: 

“It was a fantastic launch by Prostate Cancer Research, highlighting the urgent need for a targeted prostate cancer screening programme focused on those most at risk - men with a family history, Black men, and those carrying the BRCA2 gene. Darren’s powerful story, as a 45-year-old living with advanced, incurable prostate cancer, was a stark reminder of why action is so urgent. Let’s hope the National Screening Committee now gives the green light to protect this important group of men.” 

In the meantime, we urge all men over 40 to take action on their own health. Book your PSA test today - early detection can make all the difference. Find your nearest PSA testing event. 

Pictured:

• Reem Hasan, Chief Medical Officer at InHealth 
• Ben Peregrine, Business Development Director at InHealth 
• Graham Fulford MBE, Founder of GFCT